Mitigating the high cost of severe asthma requires, in part, access to the appropriate medications. Those include the five monoclonal antibodies indicated for the treatment of patients with moderate to severe asthma that were reviewed in this draft evidence report.
These medicines are clinically effective, as the report notes. Specifically, the report cites that the five therapies reduce asthma exacerbation rates by 50 percent.
Nevertheless, the report still finds that the drugs are not cost-effective at their current prices.
We urge ICER to reconsider this conclusion for two reasons.